These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32601114)

  • 1. Long-term outcomes for Asian patients with X-linked hypophosphataemia: rationale and design of the SUNFLOWER longitudinal, observational cohort study.
    Kubota T; Fukumoto S; Cheong HI; Michigami T; Namba N; Ito N; Tokunaga S; Gibbs Y; Ozono K
    BMJ Open; 2020 Jun; 10(6):e036367. PubMed ID: 32601114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Burosumab treatment of X-linked hypophosphatemia patients: interim analysis of the SUNFLOWER longitudinal, observational cohort study.
    Michigami T; Kang HG; Namba N; Ito N; Kubota T; Shintani A; Kabata D; Kanematsu M; Nishida Y; Fukumoto S; Ozono K
    JBMR Plus; 2024 Aug; 8(8):ziae079. PubMed ID: 39015507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.
    Imel EA; Glorieux FH; Whyte MP; Munns CF; Ward LM; Nilsson O; Simmons JH; Padidela R; Namba N; Cheong HI; Pitukcheewanont P; Sochett E; Högler W; Muroya K; Tanaka H; Gottesman GS; Biggin A; Perwad F; Mao M; Chen CY; Skrinar A; San Martin J; Portale AA
    Lancet; 2019 Jun; 393(10189):2416-2427. PubMed ID: 31104833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study.
    Padidela R; Nilsson O; Makitie O; Beck-Nielsen S; Ariceta G; Schnabel D; Brandi ML; Boot A; Levtchenko E; Smyth M; Jandhyala R; Mughal Z
    Orphanet J Rare Dis; 2020 Jun; 15(1):172. PubMed ID: 32605590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Burosumab: First Global Approval.
    Lamb YN
    Drugs; 2018 Apr; 78(6):707-714. PubMed ID: 29679282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives.
    Seefried L; Duplan MB; Briot K; Collins MT; Evans R; Florenzano P; Hawkins N; Javaid MK; Lachmann R; Ward LM
    Front Endocrinol (Lausanne); 2023; 14():1211426. PubMed ID: 37547321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Burosumab for Pediatric X-Linked Hypophosphatemia.
    Imel EA
    Curr Osteoporos Rep; 2021 Jun; 19(3):271-277. PubMed ID: 33970403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial.
    Whyte MP; Carpenter TO; Gottesman GS; Mao M; Skrinar A; San Martin J; Imel EA
    Lancet Diabetes Endocrinol; 2019 Mar; 7(3):189-199. PubMed ID: 30638856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical practice guidelines for paediatric X-linked hypophosphataemia in the era of burosumab.
    Sandy JL; Simm PJ; Biggin A; Rodda CP; Wall CL; Siafarikas A; Munns CF
    J Paediatr Child Health; 2022 May; 58(5):762-768. PubMed ID: 35426466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies.
    Kubota T; Namba N; Tanaka H; Muroya K; Imanishi Y; Takeuchi Y; Kanematsu M; Sun W; Seino Y; Ozono K
    Adv Ther; 2023 Apr; 40(4):1530-1545. PubMed ID: 36719566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. X-Linked Hypophosphatemic Rickets: Multisystemic Disorder in Children Requiring Multidisciplinary Management.
    Baroncelli GI; Mora S
    Front Endocrinol (Lausanne); 2021; 12():688309. PubMed ID: 34421819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.
    Linglart A; Imel EA; Whyte MP; Portale AA; Högler W; Boot AM; Padidela R; Van't Hoff W; Gottesman GS; Chen A; Skrinar A; Scott Roberts M; Carpenter TO
    J Clin Endocrinol Metab; 2022 Feb; 107(3):813-824. PubMed ID: 34636899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description.
    Brandi ML; Ariceta G; Beck-Nielsen SS; Boot AM; Briot K; de Lucas Collantes C; Emma F; Giannini S; Haffner D; Keen R; Levtchenko E; Mӓkitie O; Nilsson O; Schnabel D; Tripto-Shkolnik L; Zillikens MC; Liu J; Tudor A; Mughal MZ
    Ther Adv Chronic Dis; 2022; 13():20406223221117471. PubMed ID: 36082134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Burosumab in management of X-linked hypophosphataemia: a retrospective cohort study of growth and serum phosphate levels.
    Walker EYX; Lindsay TAJ; Allgrove J; Marlais M; Bockenhauer D; Hayes W
    Arch Dis Child; 2023 May; 108(5):379-384. PubMed ID: 36717209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching from conventional therapy to burosumab injection has the potential to prevent nephrocalcinosis in patients with X-linked hypophosphatemic rickets.
    Harada D; Ueyama K; Oriyama K; Ishiura Y; Kashiwagi H; Yamada H; Seino Y
    J Pediatr Endocrinol Metab; 2021 Jun; 34(6):791-798. PubMed ID: 33837680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets.
    Paloian NJ; Nemeth B; Sharafinski M; Modaff P; Steiner RD
    Pediatr Nephrol; 2022 Nov; 37(11):2667-2677. PubMed ID: 35211790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia.
    Ward LM; Glorieux FH; Whyte MP; Munns CF; Portale AA; Högler W; Simmons JH; Gottesman GS; Padidela R; Namba N; Cheong HI; Nilsson O; Mao M; Chen A; Skrinar A; Roberts MS; Imel EA
    J Clin Endocrinol Metab; 2022 Jul; 107(8):e3241-e3253. PubMed ID: 35533340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of patients with X-linked hypophosphatemic rickets during Covid-19 pandemic lockdown.
    Baroncelli GI; Bertelloni S; Cosci O Di Coscio M; Tyutyusheva N; D'Elios S; Peroni D
    J Pediatr Endocrinol Metab; 2021 Jul; 34(7):905-910. PubMed ID: 33887813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. X-Linked Hypophosphataemic Rickets and Growth.
    Santos Rodríguez F
    Adv Ther; 2020 May; 37(Suppl 2):55-61. PubMed ID: 32236870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children.
    Schindeler A; Biggin A; Munns CF
    Front Endocrinol (Lausanne); 2020; 11():338. PubMed ID: 32547492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.